GlassScriptPhysician profile
Giridhar Gorla
NPI 1932196516
$10,517.63
in general payments reported to CMS, 2019-2025
70 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,015 · 2020: $1,296 · 2021: $1,411 · 2022: $1,264 · 2023: $1,013 · 2024: $800 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $968.91 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Seagen INC. | $729.00 | 2019-2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $602.96 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Amgen INC. | $550.48 | 2019-2023 | Kyprolis, Blincyto |
| Novartis Pharmaceuticals Corporation | $433.49 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $418.10 | 2019-2025 | Fruzaqla, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $388.79 | 2019-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $372.73 | 2019-2024 | Jakafi |
| Pfizer INC. | $357.55 | 2019-2025 | |
| Genentech USA, INC. | $325.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $320.42 | 2019-2024 | Opdualag, Opdivo |
| Exelixis INC. | $297.21 | 2019-2025 | Cabometyx |
| Tesaro, INC. | $278.46 | 2019 | |
| Daiichi Sankyo INC. | $262.42 | 2019-2025 | Injectafer, Vanflyta, Enhertu |
| Eisai INC. | $253.73 | 2019-2021 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giridhar Gorla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.